…Background In January 2024, all people with multiple sclerosis (pwMS) treated with natalizumab (NTZ) at Oslo University Hospit…
Browse by entity family
An entity family is a category of extracted information. Choose one to browse its named entities and supporting articles.
Organisations named as supporting, sponsoring, or funding research.
5,089 articles · 9,137 mentionsInstitutionsUniversities, hospitals, research centres, networks, and public bodies.
11,350 articles · 22,378 mentionsDrugsNamed medicines, compounds, vaccines, and pharmacological agents.
10,506 articles · 58,393 mentionsDiseasesNamed diseases, disorders, syndromes, injuries, and health conditions.
23,712 articles · 125,551 mentionsTreatmentsClinical therapies and care approaches used to manage a condition.
7,227 articles · 16,644 mentionsInterventionsProgrammes, procedures, policies, and other actions being evaluated.
4,132 articles · 9,994 mentionsClinical instrumentsNamed questionnaires, scales, scores, indices, and other clinical outcome assessments.
945 articles · 1,957 mentionsPopular entities in these results
Choose an entity to see the articles in which it was identified.
Matching articles
29,499 articles · page 232 of 2459…was the most common haematological abnormality in patients with chronic liver diseases. CPS had a non-significant correlation with platelet count and …
…day 1 patency, 90-day mortality, or symptomatic ICH.Conclusions Cangrelor showed comparable safety and efficacy to GPIIb/IIIa inhibitors.…
… death and factors linked to epilepsy-related mortality.Results Epilepsy was the primary cause of death in 1584 (16.2%) of 9756 deaths o…
…nts with LVO and compare it with medical management.Methods The Chinese Pediatric Ischemic Stroke Registry (CPISR) is a multicenter, prospective observational study. Eigh…
…Introduction Critically ill patients commonly develop acquired neutrophil dysfunction, which increases susceptibility to intensive care unit-acquired…
…Objectives Colorectal cancer (CRC) is one of the most common cancers worldwide. Stage II/III…
…included. The participants (n=184) will be allocated (1:1) to a metformin dose of 1500 mg or 2250 mg per day. Outcomes include anthropome…
…d that accounted for at the individual level.Conclusion GBMSM’s HIV risk is socially patterned by a diversity of multilevel and int…
… determine if treatment with the trained immunity-based vaccine Bactek decreases the risk of unscheduled visits to healthcare professi…
…e in the primary endpoint and secondary endpoints compared with certolizumab monotherapy in participants with active RA.…
…horter PFS among patients with metastatic ccRCC treated with 1L nivolumab+ipilimumab. These findings support the concept that host body c…